Copy to clipboard 
Medartis reported 1H20 orthopedic revenue of CHF 57 million (USD $60.3 million), -11.6% vs. 1H19. Despite the impact of COVID, the company is forging ahead with its priorities of addressing regional management needs, expanding its U.S. business as well as accelerating its innovation pipeline.
Medartis appointed Lisa Thompson and Mareike Loch to executive leadership positions for North America and EMEA, respectively. Additionally, the company appointed Peter Cologna as Head of Education in June. In the U.S., Medartis expanded some territories after reviewing its sales heat map and performance metrics. The company is increasing its focus on meeting sales quotas for both distributors and sales reps.
The first half of 2020 brought several important product launches for Medartis. In April, it launched a next-generation CMF line that included 3D planning software and cutting guides. This launch marks the first time that Medartis has been able to offer surgeons digital planning tools. June brought the full launches of a forearm fracture system and CCS compression screw extension. Additional launches planned for 1H21 include mid-hindfoot correction and distal ankle fracture systems.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $52.4 | $58.0 | ($5.6) | (9.7%) |
| Other (CMF) | $7.8 | $10.2 | ($2.3) | (22.9%) |
| Total | $60.3 | $68.2 | ($7.9) | (11.6%) |
Geographic Sales
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $9.8 | $11.3 | ($1.5) | (13.1%) |
| OUS | $50.4 | $56.9 | ($6.4) | (11.3%) |
| EMEA | $33.7 | $36.7 | ($3.0) | (8.1%) |
| Asia Pacific | $11.5 | $12.2 | ($0.6) | (5.2%) |
| Rest of World | $5.2 | $8.0 | ($2.9) | (35.5%) |
| Total | $60.3 | $68.2 | ($7.9) | (11.6%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $60.3 | |
| Cost of Sales | $10.9 | 18% |
| Selling | $31.3 | 52% |
| Administration | $11.6 | 19.3% |
| R&D | $8.2 | 13.7% |
| Other | $4.4 | 7.3% |
| Net Earnings | ($6.2) | 10.2% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medartis reported 1H20 orthopedic revenue of CHF 57 million (USD $60.3 million), -11.6% vs. 1H19. Despite the impact of COVID, the company is forging ahead with its priorities of addressing regional management needs, expanding its U.S. business as well as accelerating its innovation pipeline.
Medartis appointed Lisa Thompson and...
Medartis reported 1H20 orthopedic revenue of CHF 57 million (USD $60.3 million), -11.6% vs. 1H19. Despite the impact of COVID, the company is forging ahead with its priorities of addressing regional management needs, expanding its U.S. business as well as accelerating its innovation pipeline.
Medartis appointed Lisa Thompson and Mareike Loch to executive leadership positions for North America and EMEA, respectively. Additionally, the company appointed Peter Cologna as Head of Education in June. In the U.S., Medartis expanded some territories after reviewing its sales heat map and performance metrics. The company is increasing its focus on meeting sales quotas for both distributors and sales reps.
The first half of 2020 brought several important product launches for Medartis. In April, it launched a next-generation CMF line that included 3D planning software and cutting guides. This launch marks the first time that Medartis has been able to offer surgeons digital planning tools. June brought the full launches of a forearm fracture system and CCS compression screw extension. Additional launches planned for 1H21 include mid-hindfoot correction and distal ankle fracture systems.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $52.4 | $58.0 | ($5.6) | (9.7%) |
| Other (CMF) | $7.8 | $10.2 | ($2.3) | (22.9%) |
| Total | $60.3 | $68.2 | ($7.9) | (11.6%) |
Geographic Sales
| 1H20 | 1H19 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $9.8 | $11.3 | ($1.5) | (13.1%) |
| OUS | $50.4 | $56.9 | ($6.4) | (11.3%) |
| EMEA | $33.7 | $36.7 | ($3.0) | (8.1%) |
| Asia Pacific | $11.5 | $12.2 | ($0.6) | (5.2%) |
| Rest of World | $5.2 | $8.0 | ($2.9) | (35.5%) |
| Total | $60.3 | $68.2 | ($7.9) | (11.6%) |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $60.3 | |
| Cost of Sales | $10.9 | 18% |
| Selling | $31.3 | 52% |
| Administration | $11.6 | 19.3% |
| R&D | $8.2 | 13.7% |
| Other | $4.4 | 7.3% |
| Net Earnings | ($6.2) | 10.2% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
